Strensiq is a medication used to treat hypophosphatasia (HPP), a rare genetic disorder that affects bone and mineral metabolism. However, due to its high cost and limited availability, Strensiq is only accessible through the Strensiq Managed Access Program.

The Strensiq Managed Access Program is designed to provide access to Strensiq for eligible patients who have been diagnosed with HPP but do not have access to the medication through their insurance or cannot afford it. The program is managed by Alexion Pharmaceuticals, the company that produces Strensiq.

To be eligible for the program, patients must meet certain criteria, including having a confirmed diagnosis of HPP and meeting certain financial and medical criteria. Patients must also work with their healthcare provider to complete the necessary paperwork and provide any additional information requested by Alexion Pharmaceuticals.

Once a patient is approved for the Strensiq Managed Access Program, they will receive Strensiq at no cost for a certain period of time, typically up to one year. During this time, patients will receive regular check-ins from their healthcare provider to monitor their progress and ensure that they are responding well to the medication.

It is important to note that the Strensiq Managed Access Program is only a temporary solution, as it does not provide ongoing access to Strensiq. Patients who require long-term treatment with Strensiq may need to explore other options, such as seeking financial assistance or working with their insurance provider to secure coverage for the medication.

Overall, the Strensiq Managed Access Program provides a valuable option for patients who would otherwise be unable to access this life-changing medication. By working with their healthcare provider and Alexion Pharmaceuticals, patients can receive the care they need to manage their HPP and improve their quality of life.